BACKGROUND: The vascular endothelial growth factor (VEGF) is an endothelial cell-specific mitogen involved in the process of angiogenesis, a crucial phase in tumor growth and metastasis. We carried out a case-control study to evaluate whether polymorphisms of VEGF gene modulate the risk of developing colorectal cancer disease (CCD). MATERIALS AND METHODS: We evaluated VEGF -2578A/C, -460T/C, and +405C/G genotypes obtained from a series of 302 CCD patients and 115 controls from the Italian population using polymerase chain reaction restriction fragment length polymorphism assay. RESULTS: Strong linkage disequilibrium (LD) was detected between -2578A/C and -460T/C (D' = 0.97; CI = 0.93-1) and between -2578A/C and +405C/G (D' = 0.97; CI = 0.98-1) in the case group. Complete LD was detected between -2578A/C and +405C/G and between -460T/C and +405C/G (D' = 1; CI = 0.84-1; CI = 0.82-1, respectively) in the control group. A reduced risk for the disease was associated with -2578C/A and -2578C/C (odds ratio (OR) = 0.34, CI = 0.162-0.676 and OR = 0.38, CI = 0.181-0.775, respectively). A direct association was found for carriers of the VEGF -460C/C polymorphism (OR = 3.55; CI = 1.659-8.469). We identified a protective haplotype -2578A, -460T, and +405G (OR = 0.04; CI = 0.009-0.19) and two different high-risk haplotypes -2578A, -460C, and +405G (OR = 1.90; CI = 1.31-2.27) and -2578C, -460C, and +405C (OR = 9.62; CI = 1.3-70.87). CONCLUSIONS: The present study suggests that the VEGF gene polymorphisms may play a role in the development of colorectal cancer.
BACKGROUND: The vascular endothelial growth factor (VEGF) is an endothelial cell-specific mitogen involved in the process of angiogenesis, a crucial phase in tumor growth and metastasis. We carried out a case-control study to evaluate whether polymorphisms of VEGF gene modulate the risk of developing colorectal cancer disease (CCD). MATERIALS AND METHODS: We evaluated VEGF -2578A/C, -460T/C, and +405C/G genotypes obtained from a series of 302 CCDpatients and 115 controls from the Italian population using polymerase chain reaction restriction fragment length polymorphism assay. RESULTS: Strong linkage disequilibrium (LD) was detected between -2578A/C and -460T/C (D' = 0.97; CI = 0.93-1) and between -2578A/C and +405C/G (D' = 0.97; CI = 0.98-1) in the case group. Complete LD was detected between -2578A/C and +405C/G and between -460T/C and +405C/G (D' = 1; CI = 0.84-1; CI = 0.82-1, respectively) in the control group. A reduced risk for the disease was associated with -2578C/A and -2578C/C (odds ratio (OR) = 0.34, CI = 0.162-0.676 and OR = 0.38, CI = 0.181-0.775, respectively). A direct association was found for carriers of the VEGF -460C/C polymorphism (OR = 3.55; CI = 1.659-8.469). We identified a protective haplotype -2578A, -460T, and +405G (OR = 0.04; CI = 0.009-0.19) and two different high-risk haplotypes -2578A, -460C, and +405G (OR = 1.90; CI = 1.31-2.27) and -2578C, -460C, and +405C (OR = 9.62; CI = 1.3-70.87). CONCLUSIONS: The present study suggests that the VEGF gene polymorphisms may play a role in the development of colorectal cancer.
Authors: Stacey B Gabriel; Stephen F Schaffner; Huy Nguyen; Jamie M Moore; Jessica Roy; Brendan Blumenstiel; John Higgins; Matthew DeFelice; Amy Lochner; Maura Faggart; Shau Neen Liu-Cordero; Charles Rotimi; Adebowale Adeyemo; Richard Cooper; Ryk Ward; Eric S Lander; Mark J Daly; David Altshuler Journal: Science Date: 2002-05-23 Impact factor: 47.728
Authors: Majid Shahbazi; Anthony A Fryer; Vera Pravica; Iain J Brogan; Helen M Ramsay; Ian V Hutchinson; Paul N Harden Journal: J Am Soc Nephrol Date: 2002-01 Impact factor: 10.121
Authors: Angela M Summers; Beatrice M Coupes; Mary Frances Brennan; Shirley A Ralph; Colin D Short; Paul E C Brenchley Journal: Nephrol Dial Transplant Date: 2005-07-26 Impact factor: 5.992
Authors: C G Lee; M Heijn; E di Tomaso; G Griffon-Etienne; M Ancukiewicz; C Koike; K R Park; N Ferrara; R K Jain; H D Suit; Y Boucher Journal: Cancer Res Date: 2000-10-01 Impact factor: 12.701
Authors: S W Han; G W Kim; J S Seo; S J Kim; K H Sa; J Y Park; J Lee; S Y Kim; J J Goronzy; C M Weyand; Y M Kang Journal: Rheumatology (Oxford) Date: 2004-06-22 Impact factor: 7.580
Authors: F Loupakis; C Cremolini; A Fioravanti; P Orlandi; L Salvatore; G Masi; T Di Desidero; B Canu; M Schirripa; P Frumento; A Di Paolo; R Danesi; A Falcone; G Bocci Journal: Br J Cancer Date: 2011-03-15 Impact factor: 7.640